Abbott Laboratories Stock News

Dupont (DD) is a leading specialty chemical company in the process of spinning off its electronics business, which in our view should unlock shareholder value. KKR (KKR) is a leading private equity investment firm with a large portion of earnings coming from recurring revenue sources. Alcon (ALC) revenues fell short of consensus estimates for two consecutive quarters, and management lowered its...

Dividend stocks can help meet the needs of a variety of investors. The two dividend stocks below are among the leaders in their industries.

It's been a great year for stocks, but in the past few days the bull market seems to have lost some of its mojo.

The ProShares S&P 500 Dividend Aristocrats ETF (NOBL) has underperformed SPY in 2025, with a 6.27% YTD gain versus SPY's 17.8%. Despite overall underperformance, select Aristocrats like CAT, CAH, CHRW, and IBM have delivered strong double-digit returns this year. Dividend growth for the Aristocrats in 2025 averages 5.27%, with most constituents raising payouts, though growth may not exceed 2024...

Boston Teacher Shares Life-Changing Experience with Breakthrough Dual Chamber Leadless Pacemaker During Nationwide Interviews in Conjunction with D S Simon Media Boston Teacher Shares Life-Changing Experience with Breakthrough Dual Chamber Leadless Pacemaker During Nationwide Interviews in Conjunction with D S Simon Media

Founded in 1869, Goldman Sachs is the world's second-largest investment bank by revenue and is ranked 55th on the Fortune 500 list of the largest United States corporations by total revenue.

Walmart will become the first U.S. retailer to sell an over-the-counter continuous glucose monitor in physical stores, as Abbott Laboratories' Lingo rolls out to more than 3,500 locations and online, Axios reported on Tuesday, citing the medical device maker.

The market has overreacted to ABT's lowered FY2025 organic sales growth/narrowed adj. EPS, since the management continues to deliver robust numbers while building upon FY2024 outperformance. Much of its tailwinds are attributed to the robust demand for its diabetes care offerings across continuous glucose monitors and Adult Nutrition, thanks to the ongoing GLP-1 boom. ABT has also been driving ...